Tumor Necrosis Factor-Induced Cerebral Insulin Resistance in Alzheimer’s Disease Links Numerous Treatment Rationales

Ian Clark, Craig Atwood, Richard Bowen, Gilberto Paz-Filho, and Bryce Vissel

Research School of Biology, Australian National University, Canberra, Australia (I.C.); Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin (C.A.); School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Australia (C.A.); OTB Research, Charleston, South Carolina (R.B.); John Curtin School of Medical Research, Australian National University, Canberra, Australia (G.P.-F.); and the Neurodegeneration Research Group, Garvan Institute of Medical Research, Sydney, Australia (B.V.)

Abstract

I. Introduction
II. Gonadotropins, sex steroids, tumor necrosis factor, and Alzheimer’s disease
III. Tumor necrosis factor and Alzheimer’s disease
IV. Tumor necrosis factor, amyloid β, and τ
V. Insulin
A. Insulin in basic biology and the brain
B. Insulin resistance and Alzheimer’s disease
C. Tumor necrosis factor and insulin resistance
D. Functional links of glucagon-like peptide-1 to insulin resistance
VI. Tumor necrosis factor and glycogen synthase kinase-3
VII. Tumor necrosis factor and mitochondrial dysfunction
VIII. Tumor necrosis factor and progenitor cells
A. Progenitor cells, tumor necrosis factor, and insulin resistance
B. Clock genes, controlled by tumor necrosis factor, govern progenitor activity
IX. Streptozotocin
A. Streptozotocin model for diabetes and Alzheimer’s disease
B. Streptozotocin induces tumor necrosis factor
X. The broader picture—stroke, traumatic brain injury, and infectious disease
XI. Therapeutic implications
A. Specific inhibition of tumor necrosis factor
B. Nonspecific inhibition of tumor necrosis factor
1. Thalidomide and curcumin
2. Minocycline
3. Erythropoietin
C. Administering leptin as a counter to insulin resistance
D. Administering insulin as a counter to insulin resistance
E. Glucagon-like peptide-1 mimetics and dipeptidyl peptidase-4 inhibitors as counters to insulin resistance
F. Glycogen synthase kinase-3 antagonists
H. Apolipoprotein E mimetics and bexarotene
XII. Conclusions
References
Abstract—The evident limitations of the amyloid theory of the pathogenesis of Alzheimer's disease are increasingly putting alternatives in the spotlight. We argue here that a number of independently developing approaches to therapy—including specific and non-specific anti-tumor necrosis factor (TNF) agents, apolipoprotein E mimetics, leptin, intranasal insulin, the glucagon-like peptide-1 mimetics and glycogen synthase kinase-3 (GSK-3) antagonists—are all part of an interlocking chain of events. All these approaches inform us that inflammation and thence cerebral insulin resistance constitute the pathway by which to focus for a successful clinical outcome in treating this disease. The key link in this chain presently absent is a recognition by Alzheimer's research community of the long-neglected history of TNF induction of insulin resistance. When this is incorporated into the bigger picture, it becomes evident that the interventions we discuss are not competing alternatives but equally valid approaches to correcting different parts of the same pathway to Alzheimer’s disease. These treatments can be expected to be at least additive, and conceivably synergistic, in effect. Thus the inflammation, insulin resistance, GSK-3, and mitochondrial dysfunction hypotheses are not opposing ideas but stages of the same fundamental, overarching, pathway of Alzheimer's disease pathogenesis. The insight this provides into progenitor cells, including those involved in adult neurogenesis, is a key part of this approach. This pathway also has therapeutic implications for other circumstances in which brain TNF is pathologically increased, such as stroke, traumatic brain injury, and the infectious disease encephalopathies.

I. Introduction

Despite its increasingly high incidence, harmful effects on people and society, and the considerable funding directed toward understanding its mechanism, differing ideas on the driving force of Alzheimer's disease (AD) remain unresolved. For decades, the bulk of the research effort has been focused by the wealth of logic in the idea that amyloid β (Aβ), the major neurohistological hallmark of this condition, triggers the onset of disease. This approach was very encouraging in mouse studies (Huang et al., 1999; Hung et al., 2008), but the negative outcome of recent human trials, including when amyloid was confirmed to have been reduced (Holmes et al., 2008; Green et al., 2009; Salloway et al., 2009; Extance, 2010), has led to much reassessment and repositioning that has led to lucid arguments for nonfailure of the amyloid model itself (Karran et al., 2011; Sperling et al., 2011). These negative human trials may have also led to wider acceptance of AD research that has thrown the net wider, taking into account the pathophysiology this disease shares with a range of conditions, both infectious and noninfectious. This has allowed ideas such as the cerebral insulin resistance model (de la Monte and Wands, 2008) to gain warranted prominence (Correia et al., 2011; McNay and Recknagel, 2011).

As discussed below, two therapeutic approaches already realized to be consistent with the model we are proposing are intranasal insulin and parenteral glucagon-like peptide-1 (GLP-1) mimetics. A major purpose of this review is to summarize the large volume of published evidence that, taking into account TNF and functionally similar cytokines, dramatically reinforces the likelihood that cerebral insulin resistance is indeed central, albeit somewhat downstream, in the etiology of this disease. The AD literature on leptin is also consistent with this. Here we present the case that a number of proposed treatments for AD are functionally linked, either by their capacity to lower insulin resistance or to deal with the consequences of this event (Fig. 1). These treatments include leuprolide acetate, various ways to reduce TNF levels (specific anti-TNF biological agents, and nonspecific down-regulators of TNF production (thalidomide, curcumin, and their derivatives; minocycline; erythropoietin variants; and sex steroids), the GLP-1 mimetics and dipeptidyl peptidase-4 (DPP-4) inhibitors, leptin, insulin itself, as well as glycogen synthase kinase-3β (GSK-3β) inhibitors. All are under active investigation by researchers presently coming from different perspectives.

As we also discuss, not only are extensive links between TNF and AD now reported, but also between TNF and gonadotropins as well as TNF and cell division, insulin resistance, type 2 diabetes (T2DM), mitochondrial dysfunction, and the pathologic condition caused by intracerebroventricular streptozotocin. These well documented aspects of the repertoire of TNF activity, which we suggest should become common currency in AD research, are expanded upon in this review.

II. Gonadotropins, Sex Steroids, Tumor Necrosis Factor, and Alzheimer’s Disease

Considerable evidence exists that elevated levels of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are associated with neurodegenerative disease. For examples, total brain levels of Aβ, a traditional histological marker for AD, are increased by high LH levels [such as after ovariectomy (Frye et al., 2007)], and decreased by the gonadotropin superagonist leuprolide acetate (Bowen and Atwood, 2004; Casadesus et al., 2006; Berry et al., 2008). Cogni-
tive function follows the same pattern, with low LH levels improving memory and cognition and high levels making them worse, provided LH receptors are present (Casadesus et al., 2006, 2007; Bryan et al., 2010; Ziegler and Thornton, 2010; McConnell et al., 2012). We have discussed previously the developing field of physiological sex hormone replacement therapy for AD treatment (Clark and Atwood, 2011). This is rationalized, at least in part, by the capacity of both estradiol and progesterone to reduce TNF expression in astrocytes (Kipp et al., 2007). These hormones have been reported to protect against AD (Honjo et al., 1989; Asthana et al., 2001).

Gonadotropins can regulate production of TNF, which was shown to alter cell cycle dynamics by the group that first described it (Darzynkiewicz et al., 1984). In brief, FSH has been reported to induce TNF in vitro (Iqbal et al., 2006), and high LH and FSH levels have allowed the rationalization, through their association with high TNF and IL-1β, of the onset or exacerbation of rheumatoid arthritis in women at menopause (Kåss et al., 2010). As we have noted (Clark and Atwood, 2011), the antigonadotropic actions of leuprolide render it an anti-mitotic and anti-inflammatory agent when used to treat endometriosis. In this context, leuprolide has been reported to reduce a number of inflammatory cytokines [e.g., IL-1β (Meresman et al., 2003), IL-6 (Ferreira et al., 2010; Ficicioglu et al., 2010), and monocyte chemotactic protein-1 (Khan et al., 2010)], all of which are induced by TNF (Shalaby et al., 1989; Charles et al., 1999; Mueller et al., 2010) and reduced by anti-TNF treatment (Brennan et al., 1989; Redl et al., 1996; Charles et al., 1999). Insulin resistance, commonly a TNF-induced state, and now regarded to be central to AD (see section V.B), is routinely seen in late pregnancy (Ryan et al., 1985). Late pregnancy is also a time of physiological low-grade inflammation (de Castro et al., 2011) that is plausibly regulated by the interactions of gonadotropins and TNF.

Not enough is yet known about the integration of these reproductive hormones into broader physiology and disease. Nevertheless, they already give an encouraging lead into how TNF might become excessive very early in AD (Clark and Atwood, 2011). As was TNF for years, in most minds these widely published hormones are still in a nomenclature straightjacket arising from their first description. This generates popular assumptions and limits enquiry into their relevance across wider biology. The potential for their involvement is there, because LH receptors, for example, are present on an astonishing array of cell types, ranging from thymocytes and peripheral lymphocytes (Rao et al., 2003) and macrophages (Sonoda et al., 2005) through endothelial cells (Tsampalas et al., 2010) to neurons and various microglial cells (Rao et al., 2003), as well as where one would expect them to be from the gonadotropin function of LH.

### III. Tumor Necrosis Factor and Alzheimer’s Disease

The literature often gives the impression that TNF is the only inflammatory cytokine, and most of this review, for the sake of brevity, is no exception. TNF is at present widely regarded, mainly from experience in the field of rheumatology (Brennan et al., 1989; Charles et al., 1999), as the master cytokine that starts the inflammatory cascade. Nevertheless, mediators such as the inter-
leukin-1s (of which IL-1β is the form released into extracellular fluids) are also inflammatory and may well develop their own literature parallel to that described here for TNF. IL-1 is the most advanced in this regard (Griffin et al., 1989; Kitazawa et al., 2011). A mutual dependence of these two cytokines is evident in the brain, with reports of anti-TNF agents limiting the release of IL-1 (Terrando et al., 2010) and TNF levels being reduced when IL-1 signaling is blocked (Kitazawa et al., 2011). A number of higher numbered interleukins, such as IL-12, IL-17, and IL-22, have become functionally linked with TNF but are, so far, little studied in the brain. It also warrants noting, for clarity, that the term TNF (Carswell et al., 1975) is identical to TNF-α, the commonly seen suffix being a now-meaningless relic from when lymphotoxin was, for a limited period some years ago, referred to as TNF-β.

Although some still regard inflammation in AD as solely a secondary downstream consequence of Aβ generation (as reviewed by Zotova et al., 2010), evidence continues to accumulate (for review, see Clark et al., 2010) for excess cerebral TNF, and therefore the cascade of cytokines it initiates, to be viewed as an essential preillness step in its pathogenesis. Some time ago, higher cerebrospinal fluid (CSF) levels of TNF from 56 subjects with mild cognitive impairment, but not 25 age-matched controls subjects, were reported to predict which patients would develop frank AD (Tarkowski et al., 1994). Therefore, it is a marker, as surely as are CRP and ACT, of increased pro-inflammatory cytokines such as TNF and IL-1. One of their more telling findings was that clusterin is raised 10 years earlier in the course of the disease than is fibrillar Aβ deposition. Moreover, a metastudy has determined that CLU, the clusterin gene, is the second highest of a list of the 15 top-rated genes linked to AD on the Alzgene web-based collection (Olgiati et al., 2011). Taken together, these arguments are consistent with the key nature of inflammation in AD onset. The induction of insulin resistance, accepted for years by the wider literature to be mediated by TNF (see section V.D), is, like TNF, also a very early event in AD, even preceding the onset of minimal cognitive impairment (Baker et al., 2011). Indeed, insulin resistance has been reported to be associated with reduced executive function in older people lacking any evidence of T2DM or dementia. The concept of age-related cytokine increase driving this insulin resistance was one of the possibilities the authors considered (Abbatecola et al., 2004).

### IV. Tumor Necrosis Factor, Amyloid β, and τ

With more than 30 years of dominance of the AD literature by amyloid β precursor protein (AβPP) and its cleavage product, Aβ, it is not surprising that most pathologic conditions associated with AD, including insulin resistance, have been seen as consequences of Aβ deposition (Balaraman et al., 2006; Perry et al., 2007; Townsend et al., 2007; Li et al., 2010; Lei et al., 2011). However, current clinical trial outcomes are consistent with Aβ being little more than a marker for more relevant events (Holmes et al., 2008; Green et al., 2009; Salloway et al., 2009; Extance, 2010).

Unfortunately, the direction of AD research has a momentum that has not yet, on the whole, taken into account that Aβ is a highly TNF-dependent protein. For instance, AβPP, the centerpiece of the amyloid theory of AD pathogenesis, is induced by inflammatory cytokines, including TNF and IL-1. This is a widespread phenomenon. In addition to the fact that the promotor region of the AβPP gene is controlled by these cytokines (Ge and Lahiri, 2002), its induction by these inflammatory cytokines is reported in endothelial cells (Goldgaber et al., 1989), skeletal muscle (Schmidt et al., 2008), and 3T3 L1 adipocytes (Sommer et al., 2009) as well as brain (Brugg et al., 1995; Buxbaum et al., 1998). Its presence in brain is not confined to noninfectious diseases, being described in AIDS dementia (Stanley et al., 1994) and cerebral malaria (Medana et al., 2002). Regarding AβPP cleavage, in 2004 it was reported that IFN-γ, IL-1β, and TNF specifically stimulate α-secretase activity, with an accompanying increased production of Aβ (Liao et al., 2004). IFN-γ and TNF were subsequently shown to enhance Aβ production from AβPP-expressing astrocytes and cortical neurons, and the numbers of astrocytes expressing IFN-γ were shown to have increased (Yamamoto et al., 2007). This group also showed that 1) TNF directly stimulates β-site AβPP-cleaving enzyme (or β-secretase) expression and thus enhances β-site processing of AβPP in astrocytes and 2) that TNFFR1 depletion reduced β-site AβPP-cleaving enzyme activity, as well as learning and memory deficits (Yamamoto et al., 2007). Taken together, these data imply that anti-TNF agents should be effective AβPP cleavage inhibitors.
Data from a mouse AD model after long-term inhibition of TNF are functionally consistent with this (McAlpine et al., 2009).

In contrast, it now seems reasonably appreciated that inflammatory cytokines such as TNF mediate events downstream of Aβ. Nearly a decade ago TNF was reported to alter synaptic transmission in hippocampal slices (Tancredi et al., 1992). Several years later (Wang et al., 2005b; Rowan et al., 2007), it was shown that this earlier observation explained the ability of Aβ, through TNF, to do the same. Other researchers expanded the roles of TNF in this context (Pickering et al., 2005; Stellwagen et al., 2005). The capacity of Aβ to act as a ligand for CD14 and toll-like receptor-2 (Fassbender et al., 2004; Jana et al., 2008; Tükel et al., 2009) indicates that these findings with Aβ (Wang et al., 2005b; Rowan et al., 2007) are consistent with basic immunology, because occupancy of CD14 and toll-like receptors is how the usual bacterial- and protozoal-origin inducers of TNF operate (Beutler and Poltorak, 2001). Key support for this concept has been provided by the recent demonstration that the release of proinflammatory cytokines from astrocytes is necessary for either Aβ to be neurotoxic or τ phosphorylation to be initiated (Garwood et al., 2011). Much research on Aβ’s causing the pathological features of AD (Hardy and Selkoe, 2002; Games et al., 2006; Marwarha et al., 2010) appears yet to take this body of literature into consideration. In short, it should by now be clear that many experimental observations attributed to added Aβ might well actually be caused by the inflammatory cytokines, including TNF. This additional TNF may have added to the total load (Fig. 1), but if it were a significant contributor to the clinical outcome, we would expect the human trials of antiamyloid therapies discussed earlier to have given positive results.

Likewise, hyperphosphorylated τ, another histological sign of high cytokine activity (Medana et al., 2005, 2007; Gorlovoy et al., 2009) can be regarded as one of the obvious markers of GSK-3 (see section VI) activation subsequent to cytokine-induced insulin resistance, rather than as an essential early step in the pathogenesis of the disease. Hyperphosphorylated τ has been advocated for many years as a primary mechanism of loss of cerebral function and cell loss (Goedert, 2004; Götz et al., 2012), and mice expressing mutant human τ are reported to exhibit many of the features of AD (Takeuchi et al., 2011). However, claims for a direct harmful effect on neurons need to be reconciled with evidence of a large reversible increase in hyperphosphorylated τ, leaving function and structure able to return unscathed once experimentally induced mammalian hibernation is reversed (Härtig et al., 2007). Conceivably this particular phosphorylation, although spectacular down a microscope, may well be the least important of the myriad of other, unseen, phosphorylations caused by GSK-3 activation. In summary, we argue that the now-known complexities of the current literature on the cytokines, insulin resistance, and GSK-3 reduce the need for incorporating the traditional AD hallmark proteins, however histologically intriguing, into our model to understand the origins and mechanism of this disease.

V. Insulin

A. Insulin in Basic Biology and the Brain

Over the decades, the literature of soluble mediators referred to as cytokines or hormones (conceivably interchangeable terms) have taken unexpected turns, typically through the discovery of functions quite unrelated to those for which they first came to notice. For instance, given its original function of tumor killing (Carswell et al., 1975), it was difficult to get acceptance of any role for TNF in innate immunity or disease pathogenesis (Clark et al., 1981). Insulin receptors had already been noted to be widely distributed in the central nervous system of the rat (Havrankova et al., 1978). This unexpected information was soon followed by reports of conventional insulin and insulin receptors in flies, earthworms, and bacteria (LeRoith et al., 1981a,b). The central relevance of insulin to brain physiology was a ground-breaking revelation (for review, see Adamo et al., 1989). Clearly, these and similar developments indicate that insulin has a central importance in biological signaling.

As has recently been reviewed (Correia et al., 2011), once bound to the extracellular domain of a specific tyrosine kinase receptor, insulin causes autophosphorylation of its intracellular component, triggering a chain of tyrosine kinase activity. As these authors discuss, subsequent phosphorylation activates cascades that include phosphoinositide 3-kinase/protein kinase B (Akt).

This pathway (one of those inhibited by excess TNF) in turn phosphorylates and thereby inhibits (Cross et al., 1995) the α and β cytosolic forms of GSK-, which is a serine/threonine protein kinase with profound importance in many biological systems, including neurotransmission at the synaptic level (Smillie and Cousin, 2011). Other pathways, such as c-Jun N-terminal kinase/mitogen activated protein kinase, omitted here for brevity, are also involved. The phosphoinositide 3-kinase/Akt cascade also triggers translocation of the insulin-sensitive glucose transporter 4 to the cell surface, enhancing glucose uptake (Bryant et al., 2002). This is clearly central to mitochondrial function and therefore ATP production in AD. Nevertheless, there is ample evidence that insulin has the capacity to control memory independently of its effects on glucose uptake (Craft et al., 1996, 1999).

B. Insulin Resistance and Alzheimer’s Disease

Insulin resistance can be regarded as 1) a decreased response in the presence of normal insulin levels or as 2) the need for more insulin for a normal response (i.e., the uptake of glucose, amino acids and fatty acid by
peripheral tissues). As far as we are aware, the first suggestions that insulin function was suppressed in AD were made more than a decade ago in the context of energy metabolism (Hoyer et al., 1994, 2000). Given the many essential roles of insulin documented in neurophysiology, the consequences of alterations in cerebral insulin resistance are inevitably widespread. This review focuses on more recent studies on the control of insulin resistance, and its implications, in a number of diseases, including AD, where it is attracting much current attention from prominent groups coming from quite different directions (Correia et al., 2011; Liu et al., 2011; McNay and Recknagel, 2011).

C. Tumor Necrosis Factor and Insulin Resistance

The basic literature that spans both immunity and metabolism accepts that pro-inflammatory cytokines cause insulin resistance, and anti-inflammatory cytokines promote insulin sensitivity (Chawla et al., 2011). Nevertheless, the implications of this link have not yet reached the AD literature, even though it dwells considerably on both inflammation and insulin resistance, two of the most recognized processes associated with the disease. Likewise, an awareness of this connection adds an important additional dimension to the literature on the pathogenesis of fetal alcohol syndrome disorder. As with AD, research on this disorder contains two fields, presently discrete, that it would be useful to conceptually merge: 1) ethanol induction of TNF in vivo (Qin et al., 2008) and in vitro (Boyadjieva and Sarkar, 2010), thus harming neurons (Boyadjieva and Sarkar, 2010; Hicks and Miller, 2011), and 2) ethanol-induced insulin resistance (de la Monte et al., 2005, 2011; de la Monte and Wands, 2010). As Fig. 1 illustrates, this would open up a wider awareness of treatment possibilities for both conditions.

The causative link between TNF and insulin resistance has a long history. In 1967, insulin resistance was observed in a patient with tularemia (Shambaugh and Beisel, 1967), a condition caused by *Francisella tularensis*, a Gram-negative tick-borne coccobacillus that much later proved to be a strong inducer of TNF and its downstream cytokines (Golovliov et al., 1996). By 1974, insulin resistance had been reported in septic and traumatized patients (Gump et al., 1974) and was generated in vivo by injecting bacterial endotoxin (Chaudry et al., 1974). This same agent was shown, in 1975, to be the prototype inducer of TNF (Carswell et al., 1975). That year also saw burn injury, recognized decades later to increase TNF to a functionally important degree (Giroir et al., 1994; Boehm et al., 2010), being reported to cause insulin resistance in rats (Frayn, 1975). The endotoxin concept of insulin resistance in sepsis was extended to skeletal (Raymond, 1984) and cardiac (Raymond et al., 1988) muscle, although with no mention of TNF or other cytokines as intermediaries. Importantly, these authors proposed that a post-insulin receptor site was responsible.

In the early 1980s, after acceptance that harmful effects of bacterial endotoxin and other functionally similar agents were caused through host-origin soluble proteins (eventually termed cytokines) that were elicited from patients’ cells, these proteins were linked with induction of insulin resistance. Initially, a semipurified protein that bacterial endotoxin released from macrophages was demonstrated to cause insulin resistance in adipocytes (Pekala et al., 1983). This undefined protein, in a class then termed monokines, did not affect insulin binding or stimulation of glucose uptake. Two years later it was sequenced (Beutler et al., 1985) and found, unexpectedly, to be identical to a previously sequenced molecule, TNF (Aggarwal et al., 1985). In 1989, a group who explored this area by infecting rats with *Escherichia coli* (Lang and Dobrescu, 1989) also predicted a defect in insulin signaling distal to receptor binding but again did not mention the link, by then well established, between endotoxin from this bacterium and TNF induction (Carswell et al., 1975).

A milestone article, also in 1989 (Fraker et al., 1989), demonstrated that injecting insulin and recombinant TNF concurrently into rats prevented or significantly reduced a range of metabolic and pathological changes seen in acute TNF toxicity. Various interpretations were proposed, but none proved satisfactory. With hindsight, it seems plausible that sufficient insulin had been injected to overcome much of the insulin resistance caused by the coadministered TNF. If so, the breadth of metabolic and histological observation in this text gives an intriguing insight into the wide influence of signal modification driven by cytokine-induced insulin resistance, must still unexplored. Weiner et al. (1991) found insulin and recombinant TNF to produce potent and opposing physiological signals in adipocytes. This paved the way for groups interested in various non-AD diseases, including examples caused by infectious agents known to induce TNF, to demonstrate that this cytokine was a potent cause of insulin resistance (Lang et al., 1992; McCall et al., 1992; Davis et al., 1993; Feinstein et al., 1993; Hotamisligil et al., 1993, 1996; Li et al., 2007; Qin et al., 2007; Lorenzo et al., 2008). Feinstein et al. (1993) seem to have been the first to argue that TNF exerts a major part of its antiinsulin effect by interrupting insulin-stimulated tyrosine phosphorylation, a key observation that was confirmed in cells from knockout mice by Nieto-Vazquez et al. (2007). Much of this work was done in the context of T2DM. Newer reports from within the T2DM and AD interface discuss, as one entity, the cerebral and peripheral TNF and insulin relationship (Liu et al., 2011; Bomfim et al., 2012).

Inhibiting TNF can prevent or reverse insulin resistance. Uysal et al. (1997) showed that insulin resistance did not develop in obese mice lacking TNF function. Seven years later a series of patient studies began to
appear in which commercial anti-TNF biological agents reduced insulin resistance in T2DM (Yazdani-Biuki et al., 2004), rheumatoid arthritis [in some (Kiortsis et al., 2005; Gonzalez-Gay et al., 2006, 2010, 2012) but not all (Ferraz-Amaro et al., 2011) reports], and ankylosing spondylitis (Kiortsis et al., 2005). In addition, infliximab, one of these commercial anti-TNF biological agents, was tested in obese diabetic mice, and it improved insulin signal transduction in muscle, liver, and hypothalamus. In doing so, it completely restored the activity of insulin-induced insulin receptor, insulin receptor substrate-1, and receptor substrate-2 tyrosine serine phosphorylation (Araujo et al., 2007). In the same vein, others have reported that insulin signaling in endothelial progenitor cells, measured by the phosphorylated to total Akt ratio, was reduced by 56% on exposure to TNF (Desouza et al., 2011). Even more recently, infliximab, one of these commercial anti-TNF biological agents, was tested in obese diabetic mice, and it improved insulin signal transduction in muscle, liver, and hypothalamus. In doing so, it completely restored the activity of insulin-induced insulin receptor, insulin receptor substrate-1, and receptor substrate-2 tyrosine serine phosphorylation (Araujo et al., 2007). In the same vein, others have reported that insulin signaling in endothelial progenitor cells, measured by the phosphorylated to total Akt ratio, was reduced by 56% on exposure to TNF (Desouza et al., 2011). Even more recently, infliximab has been employed to demonstrate that the in vitro insulin resistance induced by Aβ is inhibited by neutralizing TNF (Bomfim et al., 2012).

Because treatment of AD with large anti-TNF biological agents is focused on delivering them into the CSF (section XI.B), the most AD-relevant in vivo demonstration to date of altering insulin resistance in this way has been done by Arruda et al. (2011), who showed that intracerebroventricular infliximab improved insulin signal transduction through insulin receptor substrate 1. This was accompanied by a whole-body reduction in insulin resistance.

D. Functional Links of Glucagon-Like Peptide-1 to Insulin Resistance

Certain gut peptides, the most prominent being GLP-1, have emerged as central to understanding both brain function (During et al., 2003) and insulin physiology. As has been reviewed in the context of neurodegenerative disease (Greig et al., 2004b; Hölscher and Li, 2010; Holst et al., 2011), GLP-1, an endogenous insulinotropic peptide, reduces insulin resistance (Cabou et al., 2008; Knauf et al., 2008). It was originally believed to arise only from L cells in the distal ileum and colon but is now intensively studied as a peptide of brain origin, with key brain functions. GLP-1 and its mimetics provide a set of signals that are the reverse of those (e.g., regarding Akt and c-Jun N-terminal kinase) generated by excess TNF (Li et al., 2005; Ferdaoussi et al., 2008; Natalicchio et al., 2010). Consequently, GLP-1 mimetics have the capacity to reduce insulin resistance in ways shared by exogenous anti-TNF agents. Because GLP-1 is rapidly degraded in vivo, degradation-resistant analogs have been developed and are in therapeutic use for T2DM. As discussed in section XI.F, these agents also show promise in AD models.

VI. Tumor Necrosis Factor and Glycogen Synthase Kinase-3

In the literature, GSK-3β predominates over the very similar GSK-3α form and, for simplicity, is referred to exclusively in this text. As with a number of other molecules with very high profiles, the fame of GSK-3β has not rested not on its first description [arising from the capacity to phosphorylate and thence inactivate glycogen synthase (Embi et al., 1980)] but on the gradual realization of its very great number of substrates, more than 50 of them documented by 2003 (Dobie and Woodgett, 2003). Fifteen years earlier, TNF had caused a similar stir when, as a cytokine still traditionally linked in most minds only to tumor necrosis, it was noted to possess a remarkably high number of physiological as well as pathological functions (Nathan, 1989). We have previously discussed this in the CNS context (Clark et al., 2010). In hindsight, this information contained the potential to have opened minds to the possibility of a functional link between these two strikingly pleiotropic molecules associated with normal physiology, innate immunity, and inflammation.

As with TNF, many groups are interested in the roles of GSK-3β in brain function. Over the years, those arguing for a primary role for hyperphosphorylated τ in AD pathogenesis have, as expected, focused on GSK-3β as the phosphorylating kinase that generates this form of τ (Mandelkow et al., 1992; Lovestone et al., 1994; Lovestone and Reynolds, 1997). Other have examined its effects on the brain itself and produced much compelling data suggesting that GSK-3β, in its inhibited state, is essential for normal brain function, and its activated state leads to the array of functional loss seen in AD (Jope and Johnson, 2004; Balaraman et al., 2006; Engel et al., 2006; Hooper et al., 2007; Kimura et al., 2008; Salcedo-Tello et al., 2011; Smillie and Cousin, 2011). As noted in section VI, the argument that whenever GSK-3β activation is high, the hyperphosphorylated τ generated initiates disease (Goedert, 2004) has yet to explain the reported harmlessness of this protein in induced mammalian hibernation (Hartig et al., 2007). Certainly, the position of hyperphosphorylated τ in Fig. 1 is reinforced by the evidence that it is reduced when the tap is turned off at the top of the cascade by LH ablation (Lin et al., 2010), anti-TNF (Shi et al., 2011), IL-1 signaling blockade (Kitazawa et al., 2011), minocycline (Garwood et al., 2010), sex steroids (Carroll et al., 2007), or additional insulin (Hong and Lee, 1997).

TNF and GSK-3β have proved to be functionally linked, both in physiology and disease pathogenesis. Insulin resistance, a phenomenon readily caused by TNF (see section V.C), has long been known to influence GSK-3β activity (for review, see Jope 2004; Jope and Johnson, 2004). As noted above (Fraker et al., 1989), insulin also reduces the harmful effects of excess TNF production, as do sex steroids (e.g., (Jiang et al., 2009).
In addition, the reduction of endotoxin and peptidoglycan-induced pathologic conditions in rats by insulin, independent of blood glucose changes, has been demonstrated to involve GSK-3 inhibition (Dugo et al., 2006). Others reported that the insulin resistance and associated increase in GSK-3β activity in brains of a mouse model of T2DM, as well as what the authors noted were learning difficulties parallel to those seen in AD, were corrected by administering insulin (Jolivalt et al., 2008). Moreover, the specific GSK-3β inhibitor 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763) altered the cytokines released from endotoxin-stimulated human monocytes to a strongly anti-inflammatory profile (Martin et al., 2005). Nevertheless, the separation of the two in the minds of most researchers has led to the existence of both inflammatory and GSK-3 models of AD. Rarely are they discussed together, and then only in terms of post-Aβ secondary inflammation, not as two sub-units of an essential component of disease initiation (Hooper et al., 2008).

VII. Tumor Necrosis Factor and Mitochondrial Dysfunction

As we have reviewed previously (Clark et al., 2010), the concept of dysfunctional mitochondria, and thus poor oxygen utilization and energy production, is important in understanding disease pathogenesis. This seems to have been first suggested, on the basis of organelle electron microscopy, in malaria (Maegraith, 1954). Nearly 20 years later, it appeared in the sepsis literature (Mela et al., 1972). A further 2 decades later, TNF, by then well established as a key mediator in infectious disease, was first demonstrated to suppress mitochondrial respiration (Stadler et al., 1992). By the end of that decade, extensive functional studies in this context were begun (Fink, 1997, 2000, 2001), and the general reasoning was extended to HIV dementia (Krumlan et al., 1999) and influenza encephalopathy (Yokota, 2003). More recent research on TNF’s ability to induce mitochondrial dysfunction (Chen et al., 2010) again noted that direct treatment with TNF led to reduced intracellular ATP and more generation of reactive oxygen species. More significantly, the anti-TNF biological agent etanercept has been shown to ameliorate cardiac mitochondrial dysfunction in vivo (Moe et al., 2004). Systemic mitochondrial dysfunction, as part of cytokine-induced inflammation, is still very topical in the pathophysiology of sepsis (Garrabou et al., 2012).

Mitochondrial dysfunction has an early onset in AD (Hauptmann et al., 2009) and is widely regarded as important in its pathogenesis (Castellani et al., 2002). Although the first group to propose mitochondrial functional defects as a mechanism for AD was primarily interested in oxidative stress as a mechanism (Blass and Gibson, 1991), it did not take long for researchers of Aβ, by then dominating AD disease pathogenesis, to incorporate the mechanism of mitochondrial dysfunction into their reasoning (Kaneko et al., 1995). This view persists to the present day (Borger et al., 2011) and has remained largely unquestioned despite the implications of the prevalence of TNF in AD brains (section III) and the widely published capacity of this cytokine to induce both AβPP and Aβ (section IV) and to directly cause mitochondrial dysfunction (see above). Young-Collier et al. (2012) found that the reduced expression of mRNA of genes responsible for mitochondrial function in human AD neurons could not be duplicated with 3 days of culture with Aβ (instead, expression rose); this might now encourage investigation into other possible mechanisms for the finding.

Does mitochondrial dysfunction precede or follow insulin resistance? Both viewpoints appear in the literature, with discussion of excessive fat intake being common to several articles arguing that mitochondrial dysfunction occurs first (Anderson et al., 2009; Rector et al., 2010). In contrast, a study designed to investigate the mitochondrial dysfunction during fasting concluded it was a consequence rather than a cause of insulin resistance (Hoeks et al., 2010). Indeed, when associated with cell death or apoptosis, mitochondrial dysfunction is reported to occur after GSK-3β activation (Petit-Paitel et al., 2009; Wang et al., 2011), placing it after insulin resistance (Fig. 1). Its position here is consistent with experiments in which the mitochondrial dysfunction induced by SZT, an agent that mimics T2DM or AD (section IX.A), was corrected by administering insulin (Chowdhury et al., 2010). Clearly, this implies that improved cerebral mitochondrial function is a plausible consequence of treating AD with intranasal insulin (section XI.E; Fig. 1).

VIII. Tumor Necrosis Factor and Progenitor Cells

A. Progenitor Cells, Tumor Necrosis Factor, and Insulin Resistance

Adult neurogenesis, which is low or absent in the shrunken brains of patients with AD, is essential for normal memory formation (Clark et al., 2010). Such progenitor activity, requiring activin A (Abidipranoto-Cowley et al., 2009), is part of a normal organism-wide pattern in which such cells are controlled by a sex hormone-TNF pathway to maintain cellular homeostasis. The dynamic regulation of neurogenesis by hypothalamic-pituitary-gonadal axis hormones, including activins, gonadotropins, and sex hormones, particularly progesterons, is well established (Vadakkadath Meethal and Atwood, 2005). However, the sequence of events through which sex hormones seem to modulate TNF during control of progenitor cells is not yet known. Despite this incomplete picture, the literature to date is consistent with the idea that increased TNF induces insulin resistance, and thus GSK-3β activation (Verhees et al.,
2011), and constitutes the major pathway in progenitor cell homeostasis.

T2DM is a good example of a disease combining chronic systemic inflammation, insulin resistance, and widespread defects in progenitor cell function. It is telling that it should both predispose to AD (Arvanitakis et al., 2004) and share cerebral insulin resistance with this condition (Liu et al., 2011). The details of the signaling deficits are also the same (Liu et al., 2011). In neurogenesis (and, as far as has been examined, a general rule in other progenitors), physiological levels of TNF and its downstream cytokines enhance proliferation, whereas supraphysiological levels inhibit proliferation (Bernardino et al., 2008). This phenomenon has been demonstrated in thymocytes (Ranges et al., 1988; Hernández-Caselles and Stutman, 1993), hepatocytes (Bour et al., 1996; Diehl and Rai, 1996), hematopoiesis (Clark and Chaudhri, 1988; Rebel et al., 1999) and, of plausible relevance to data from AD brains (Sheng et al., 2012), impaired mitochrondia biogenesis (Valerio et al., 2006). The relevance of TNF-induced insulin resistance to the pathogenesis of the widespread degenerative change that characterizes chronic inflammatory diseases can be gleaned from the literature on endothelial cell progenitors (Cubbon et al., 2009; Abbas et al., 2011; Desouza et al., 2011) and thus nephropathy; muscle progenitors (Pajak et al., 2008) and thus cachexia; fibroblast progenitors (Frankel et al., 2006; Goren et al., 2006; Siqueira et al., 2010) and thus poor wound healing; cartilage progenitors (Ablowi et al., 2009; Kayal et al., 2009) and thus poor fracture repair; and erythroblasts (Tsinkalovsky et al., 2007) and thus the anemia of chronic disease. Whether the recorded protective effect of sex hormones in some of these circumstances is an independent property parallel to their ability to reduce production of TNF (He et al., 2004; Kipp et al., 2007) is a yet to be tested. We note, however, that estrogen has been reported to promote cutaneous wound healing (Campbell et al., 2010) by means other than its anti-inflammatory mechanism. Nevertheless, the poor wound healing in rheumatoid arthritis, a condition exhibiting insulin resistance, is a condition exhibiting insulin resistance reversible by anti-TNF agents (Kiortsis et al., 2005; Gonzalez-Gay et al., 2006), has been reported to be countered by anti-TNF treatment (Shamagum et al., 2011). Although on a small scale, this study is intriguing, because conventional wisdom, predicated on the idea that such anti-TNF treatment has the potential to suppress immunity against certain pathogens that could infect wounds, would have us expect the opposite outcome. As might be expected, elevated levels of sex steroids, such as during pregnancy or after hormonal replacement therapy, and known to suppress TNF, leads to diminished disease activity in rheumatoid arthritis (Ostensen et al., 1983; Kanik and Wilder, 2000; Islander et al., 2011). In contrast, the disease is often aggravated after parturition (Ostensen et al., 1983).

B. Clock Genes, Controlled by Tumor Necrosis Factor, Govern Progenitor Activity

The control of progenitor cells homeostasis by TNF is not only a small part of the broader control that tissue clocks exert in all tissues through circadian, or clock, genes. Indeed, cell division in general is under their control (Matsuo et al., 2003). Likewise, the normal diurnal cycles in food intake, sleep, insulin requirements, and mitochondrial function, kept in their normal circadian patterns when these genes remain under physiological diurnal fluctuations of sex hormones, TNF and downstream cytokines (Kohsaka and Bass, 2007), run amok in well documented ways during illness (Hart, 1988; Bluthe et al., 1994; Dantzer and Kelley, 2007). For as long as TNF and IL-1β are in pathological disease-induced excess, clock genes undergo a longer-term suppression (Cavadini et al., 2007). Hence mechanisms governed by clock genes, including cell cycling (Matsuo et al., 2003), can be expected to undergo pathological change. Several years ago we proposed that such suppression can explain the pattern of pathology that characterizes severe bacterial, protozoal, viral and post-trauma disease (Clark et al., 2008).

Among the clock genes suppressed by excess TNF and IL-1β are the period genes, Per1, Per2 and Per3 and the central, interconnecting, response element clock gene, rev-erba (Cavadini et al., 2007). The existence of an essentially parallel literature on reproductive hormones and clock genes (Nakamura et al., 2008; Nakamura et al., 2010; Karatsoreos et al., 2011) again demonstrate the present minimal awareness of the functionally important adjacent positions of sex hormones and TNF in the same regulatory pathway. Certain clock genes have been demonstrated to undergo insulin-dependent regulation (Tahara et al., 2011), and to control adult neurogenesis, including in the hippocampus (Moriya et al., 2007; Borgs et al., 2009; Kimiwada et al., 2009), as well as endothelial cell (Wang et al., 2008) and cartilage (Mengatto et al., 2011) progenitors. Of particular relevance here are the data from experiments published in 2004 (Kuriyama et al., 2004) in which the normal circadian clock oscillation, present in all tissues, was examined in heart and liver of mice in which diabetes was generated with STZ. Per2 was diurnally inhibited, but this could be corrected by injecting insulin, i.e., by overcoming insulin resistance. This is consistent with glucagon-like peptide-1 (GLP-1) mimetics, clinically useful against T2DM because of their ability to correct insulin resistance (see next Section), promoting neurogenesis in AD models (Hamilton et al., 2011; Holst et al., 2011). Predictably (Jope and Johnson, 2004), the degree of activation of GSK-3β proves to be what ultimately controls the clock genes, and thus proliferation (Hirota et al., 2008; Ko et al., 2010; Kozikowski et al., 2011). Again as expected, phosphorylation of GSK-3β itself normally un-
derores robust circadian oscillation, and it readily phosphorlates Per 2 (Iitaka et al., 2005).

Taken together, the wider progenitor cell literature is therefore consistent with inhibition of neurogenesis in AD by excess brain TNF through a pathway that involves inhibition of clock genes by insulin resistance, thus damping down or switching off progenitor cells. Evidence also incriminates chronic inflammation in reduced recruitment of new neurons into the hippocampal networks that underlie memory consolidation (Belarbi et al., 2012a). Inhibited neurogenesis and distorted cell cycling (Yang and Herrup, 2007) in AD are but two consequences of this widely applicable principle in disease pathogenesis. Logically speaking, AD is therefore susceptible to treatment with any of the approaches discussed herein that rectify insulin resistance. Moreover, the main stages of this pathway are recognized general principles as much at home in physiology [e.g., in the metabolic shutdown of hibernation (Stieler et al., 2011) and dauer, or suspended animation, forms of the nematode Caenorhabditis elegans (Tissenbaum and Ruvkun, 1998; Forsythe et al., 2006)] as in other human diseases beyond AD and T2DM, including stroke (Valerio et al., 2011) and depression (Li and Jope, 2010) (Fig. 2). These last two conditions have an emerging literature on therapy with anti-TNF biological agents (Uguz et al., 2009; Tobinick, 2011).

IX. Streptozotocin

A. Streptozotocin Model for Diabetes and Alzheimer’s Disease

SZT, originally isolated from Streptomyces achromogenes for use as an antibiotic (Vavra et al., 1959), was later realized to be a potent diabetogenic agent (Junod et al., 1967); since then, it has had an important role in diabetes research. In 1983, awareness developed that SZT, besides leading to pancreatic β-cell destruction, also inhibits metabolic responsiveness to insulin rather than its binding to its receptor (Hansen et al., 1983). A decade later it was appreciated that intracerebroventricular injection of SZT produces changes in glucose metabolism that parallel those seen in AD (Plaschke and Hoyer, 1993); subsequently, its ability to bring about a wide range of the changes seen in AD began to be uncovered. For example, rats receiving intracerebroventricular injections of SZT, which does not alter systemic glucose metabolism, develop insulin receptor defects and thus insulin resistance (Hoyer et al., 2000). They also exhibit brain atrophy, neurodegeneration, gliosis, and increased immunoreactivity for activated GSK-3β and hyperphosphorylated τ, as observed in AD (Lester-Coll et al., 2006). This model is seen as increasingly important because, in contrast to genetically generated mouse strains that dominate the experimental literature, it closely resembles the most common human condition, termed sporadic AD. There is now a considerable literature on the use of SZT to establish models of insulin resistance (Blondel and Portha, 1989; Koopmans et al., 2006; Cheng et al., 2010; Thackeray et al., 2011). As reviewed previously (de la Monte and Wands, 2008), these SZT-induced changes could be reduced or prevented by early treatment with peroxisome proliferator-activated receptor agonists in doses smaller than routinely used to treat diabetes type 2. TNF down-regulates certain peroxisome proliferator-activated receptor receptors (Beier et al., 1997).

B. Streptozotocin Induces Tumor Necrosis Factor

The capacity for SZT to induce TNF has been documented since the mid-1990s (Sagara et al., 1994; Herold et al., 1996). Cai et al. (2011) reported that it increases TNF and IL-1β in rat hippocampus. This activity of SZT to induce TNF has been exploited to help understand the consequent pathologic features of diabetes (Sagara et al., 1994; Holstad and Sandler, 2001; Zauli et al., 2010; Devaraj et al., 2011). Specific examples include diabetic cardiomyopathy (Westermann et al., 2007) and diabetic nephropathy (Mensah-Brown et al., 2005; Navarro et al., 2005). In the latter, successful experimental treatments include combined insulin (overcoming insulin resistance) and curcumin [reducing the inflammatory response (Sharma et al., 2007)] as well as curcumin alone (Sotiropou et al., 2011). A commercial anti-TNF biological agent has also been used, to good effect, for this purpose (Yamakawa et al., 2011). As far as we are aware, Isik et al. (2009) are the only researchers to use an anti-inflammatory approach (curcumin) to rationalize post-SZT insulin resistance. As might be expected from the interplay between reproductive hormones and TNF, sex steroids are well recognized to reverse post-SZT insulin resistance and protect from insulin resistance in rats exhibiting SZT-induced diabetes (Coleman et al., 1982; Ordonez et al., 2008). Surprisingly, the consensus from
this literature (i.e., that neutralizing excess TNF is a logical step in alleviating pathologic features of diabetes) has yet to translate across to research that uses SQT to duplicate AD. This should prove to be an excellent model in which to develop a close laboratory-based understanding of the effects of anti-TNF agents and sex hormones in this disease.

X. The Broader Picture—Stroke, Traumatic Brain Injury, and Infectious Disease

This review focuses on the pathogenesis of AD, with some reference to T2DM, but the gist of the pathway we have constructed (Fig. 1) evidently extends to understanding other encephalopathies in which cerebral TNF is increased by routes with current explanations other than LH/FSH (Section II). Stroke, traumatic brain injury (TBI), and brain involvement in malaria, a systemic infectious disease, are examples (Fig. 3). As summarized by Simpkins et al. (2009), AD, stroke and TBI tend to become one syndrome with the passage of time since onset. Moreover, TBI is often seen and postcerebral malaria syndrome is usually seen (Boivin et al., 2007; Kihara et al., 2009; Idro et al., 2010) in the young, before reproduction or menopause.

Induction of TNF in the penumbra of brain ischemia, the area surrounding the region worst affected by the vascular obstruction, involves glutamate and nuclear factor-kB (Kaushal and Schlichter, 2008) and is inhibited by regulatory T cells (Liesz et al., 2009). Cerebral ischemia has also been reported (Wen et al., 2004a) to induce aberrant neuronal cell cycle re-entry that can be reduced by 17β-estradiol, an inhibitor of TNF (Hsu et al., 2000), a cytokine with a long history of interfering with mitosis (Darzynkiewicz et al., 1984) and more recently demonstrated to cause aneuploidy (Wu et al., 2011), the phenomenon that sets the scene for aberrant cell cycling and thus apoptosis. As recently reviewed by Clark et al. (2010), trauma triggers release of inflammatory cytokines through the action of mitochondrial DNA.

![Diagram](image)

**Fig. 3.** Examples of the range of different inducers, in different diseases, that can lead to increased cerebral TNF and hence clinically similar outcomes.

set free from disrupted cells (Zhang et al., 2010). In infectious diseases, much evidence exists for the direct induction of TNF by products of the pathogen, beginning with the example of bacterial lipopolysaccharide in the original TNF article (Carswell et al., 1975). For instance, ample evidence exists for the malaria toxin as a TNF inducer (Bate et al., 1989; Tachado and Schofield, 1994). As with AD and T2DM, insulin resistance is documented in stroke (Caldeira et al., 2011), TBI (Mowery et al., 2009; Ley et al., 2011), and cerebral malaria (Eltahir et al., 2010b). Likewise, Aβ and hyperphosphorylated τ, the proteins widely regarded as AD hallmarks and appreciated to be indicators of chronically high TNF (section IV) and GSK-3 hyperactivation induced by insulin resistance (section VI), respectively, are also present in stroke (Irving et al., 1996; Nihashi et al., 2001; Wen et al., 2004b), TBI (Irving et al., 1996; Smith et al., 2003; Tran et al., 2011), and cerebral malaria (Medana et al., 2002, 2005).

Before expanding on the encephalopathies of systemic infectious diseases, we recall the proposal that the Aβ induced in AD (Bowen et al., 2004) and deposited in the cerebrovasculature is a response, albeit sometimes an insufficient one, to seal these vessels to minimize blood-brain barrier (BBB) breakdown (Atwood et al., 2002; Atwood, 2010). These arguments, developed in part to explain the neuroinflammatory reaction frequently observed during normal aging (Wilson et al., 2008), provide a plausible novel amyloid-based degree of complexity to the development of the BBB changes commonly seen in the encephalopathies of infectious disease. For instance, this reasoning plausibly applies to the AβPP present in cerebral malaria brains (Medana et al., 2002). In addition, the antimicrobial properties of its cleavage product, Aβ (Soscia et al., 2010), can be expected to minimize secondary bacterial invasion (a common problem in malaria because of immunosuppression) at this critical location. The association of BBB lesions with TNF generated by infectious agents is already in place in the encephalopathies associated with sepsis (Alexander et al., 2008), trypanosomiasis (Quan et al., 1999; Kristensson et al., 2010), malaria (Adams et al., 2002) influenza (Ichiyama et al., 1996), and AIDS (Mastroianni et al., 1990; Nolting et al., 2009).

Research on cerebral insulin resistance and GSK-3 activation is sparse regarding the encephalopathies of infectious disease, although some publications link systemic insulin resistance with poor cognitive performance in women infected with HIV (Valcour et al., 2012) and fatal malaria with cerebral symptoms (Eltahir et al., 2010a).

XI. Therapeutic Implications

A. Specific Inhibition of Tumor Necrosis Factor

The obvious way to capitalize on the relationship between inflammation and insulin resistance is to specifi-
cally neutralize excessive TNF, as is widely recognized to be useful in a number of systemic, but not cerebral, inflammatory diseases. Clearly, this limitation is imposed by the large molecular size of current therapeutically successful specific anti-TNF biological agents, such as infliximab and etanercept, which precludes their passage through the blood-brain barrier when administered subcutaneously or intravenously. Indeed, a negative result (a small 24-week double-blind trial) with subcutaneous etanercept against AD has been reported (Bohac et al., 2002), as has a positive mouse intracerebroventricular injection trial, albeit measuring only the indirect indicator Aβ (Shi et al., 2011). Because the intracerebroventricular route is a precarious one, unsuited to regular administration to the same patient, a number of ways to circumvent this problem are being developed to widen the use of these highly successful biological agents to a new patient group. The earliest of these is a novel approach termed the perispinal route (Tobinick et al., 2006, 2010, 2012). Its logic depends on 1) a short period of head-down tilting to gain a gravitational advantage, 2) an awareness of anatomy of Batson’s plexus [a valveless venous system that surrounds the spinal column in continuum with the choroid plexus (Nathoo et al., 2011)], and 3) knowledge of the effect of acute hypertension on choroid plexus permeability [a 30-fold increase in albumin in CSF within 10 min of pharmacologically induced acute local hypertension (Murphy and Johanson, 1985)]. Not surprisingly, therefore, the gravitational effect on this valveless blood column of a 5-min head-down tilt of head and trunk has been reported, in anesthetized rabbits, to increase dramatically the passage of albumin and globulin, molecules of etanercept size, from plasma to the cerebrospinal fluid (Wen et al., 1994). The authors noted that this would be a useful way to get large molecules into the CSF for therapeutic purposes.

The apparent indifference of the makers of etanercept to the claims of the perispinal anti-brain TNF approach to treating AD (Tobinick et al., 2006; Tobinick and Gross, 2008) has not deterred other investigators from aspiring to the same outcome by several approaches. One group is developing what it refers to as a molecular Trojan horse decoy receptor system to get a similar anti-TNF fusion molecule into the brain (Pardridge, 2010; Zhou et al., 2011). Others (http://www.neurokine.com/index-3.html) employ encapsulation of etanercept in liposomes, a well recognized technology (Paolino et al., 2011), to get the same result. It is encouraging that this web site notes Dr. Patrick McGeer, a long-time exponent of earlier approaches to minimizing brain inflammation (McGeer and McGeer, 1995), as a consultant. Another approach under way is to devise anti-TNF nanoantibodies small enough to pass the BBB (Harmsen and De Haard, 2007; Vandenbroucke et al., 2010).

It warrants noting here that the dual activity of TNF as a component of innate immunity and disease pathogenesis has made it inevitable that certain infections, particularly tuberculosis and those caused by certain protozoa, have a tendency to be exacerbated during long-term anti-TNF therapy. This has been comprehensively reviewed (Clark et al., 2010). The very extensive use of this treatment in a number of inflammatory diseases, particularly rheumatoid arthritis, demonstrates that this challenge can be managed successfully.

B. Nonspecific Inhibition of Tumor Necrosis Factor

1. Thalidomide and Curcumin. Brain TNF levels can also be diminished therapeutically by thalidomide (Alkam et al., 2008; Ryu and McLarnon, 2008) or its derivatives (Greig et al., 2004a; Tweedie et al., 2007; Belarbi et al., 2012b), and current research programs are examining this in an AD context. Likewise, curcumin, a long-appreciated inhibitor of TNF (Chan, 1995), is used for this purpose in its original form (Cole et al., 2007) as well as more effective (i.e., in terms of brain entry) derivative forms (Chiu et al., 2011; Tsai et al., 2011). All of the authors whose work is cited in this section might have unwittingly been improving insulin signaling as well as achieving their stated aims, but this remains unexplored. The exception appears to be IIsik et al. (2009), who employed the anti-inflammatory activity of curcumin to examine its effects on both insulin resistance and memory in a rat model of SZT-induced AD. Curcumin is also reported to protect testosterone-producing Leydig cells and pancreatic cells from toxicity (Giannessi et al., 2008).

2. Minocycline. Minocycline is a particularly broad-spectrum oral tetracycline that was synthesized from a naturally occurring antibiotic decades ago (Church et al., 1971). Being the most lipid-soluble of this class of drug, it enters the brain more readily than the rest. Although not without side effects, it has been known for 15 years to be anti-inflammatory in vivo (Tilley et al., 1995), and its avid brain penetration is responsible for the attention it has received in the neuroinflammation literature (Peng et al., 2006). It is often termed an inhibitor of microglial activation, and the list of inflammatory cytokines it down-regulates, in brain and elsewhere, includes TNF and IL-1β (Célérié et al., 1996; Lee et al., 2004; Suk, 2004; Wang et al., 2005a). Consistent with the overarching pathway central to this review, minocycline shows experimental promise as a treatment, complementary to the others we discuss, for the various manifestations of excess production of these cytokines in the brain (Familián et al., 2006; Seabrook et al., 2006; Choi et al., 2007; Fan et al., 2007; Noble et al., 2009). A human AD trial with minocycline is under way (http://clinicaltrials.gov/ct2/show/NCT01463384).

3. Erythropoietin. Another endogenous humoral factor, these days referred to as a cytokine but described decades before this term was in use, is erythropoietin (EPO). It was discovered as a hormone that drives erythropoiesis and thus provides the means to deliver more
oxygen to tissues. Apart from its large-scale clinical use in treating chronic anemias, it gained notoriety as a performance-enhancing drug, in due course an illegal one, in sports. EPO warrants mention in this section as a performance-enhancing drug, in due course an illegal systemic inflammatory diseases that may develop an adverse pro-inflammatory milieu, and TNF is almost always on the radar screen of clinicians caring for any of these conditions. As noted (Clark et al., 2011), this pattern had previously escaped recognition. A case for the centrality of insulin resistance in AD is further strengthened by the opposite effects on insulin resistance of leptin (German et al., 2010; Koch et al., 2010) and TNF, leptin reducing insulin resistance TNF induces (Meistrell et al., 1997; Valerio et al., 2006; Alkam et al., 2008; Bernardino et al., 2008; Cubbon et al., 2009; Chio et al., 2010; Chen et al., 2011). Thus, the concept of endogenous anti-TNF activity being one of the biological roles of EPO is very plausible, as is harnessing this attribute for disease therapy. Unfortunately, the long history of indifferent recombinant EPO trials in disease has been clouded by a propensity for its erythropoietic properties to dominate, with a sometimes fatal thrombosis a feature of its chronic use (Patel et al., 2011a). Thus nonerythropoietic variants of this molecule are being developed. They fall into two main categories: carbamylated EPO (Ramirez et al., 2009; Leconte et al., 2011) and nonerythropoietic tissue-protective proteins that mimic the three-dimensional structure of EPO, such as pyrogulutamate helix B-surface peptide (Patel et al., 2011b). Hand and Brines (2011) and Sölling (2012) have reviewed this area. Information such as toxicity and efficacy within the wide range of activities of native EPO is still being gathered for these variants.

The retarded neurogenesis seen in infection with Japanese encephalitis virus has been reported to be reversible by abrogating the inflammatory response of microglia, including TNF production, with exposure to minocycline (Das et al., 2011). Protection against simian cerebral pathologic conditions related to HIV by minocycline has also recently been recorded (Ratai et al., 2010; Campbell et al., 2011). Therefore, it warrants testing whether all of the above reasoning applies to possible treatments for the encephalopathies of systemic infectious disease.

As noted above, malaria comes into the category of systemic inflammatory diseases that may develop an associated encephalopathy. This condition in children in tropical Africa is also noteworthy for a well-documented AD-like syndrome that can follow acute cerebral symptoms, despite recovery from systemic disease. This syndrome correlates with CSF levels of TNF and exhibits long-term cognitive impairment, including deficits in memory, attention, visuospatial skills, language, and executive function (Carter et al., 2005; Boivin et al., 2007; John et al., 2008a,b; Kihara et al., 2009). This condition is also noted for aggressive behavior (Idro et al., 2010), as is AD (Ballard and Walker, 1999). We have reviewed the literature linking TNF with aggression (Clark et al., 2010). Researchers were alerted to the possible implications of the tissue-protective aspects of EPO in malaria through evidence that its recombinant form lowered TNF levels and prevented cerebral complications and death in a mouse model of the disease (Kaiser et al., 2006). Raised serum levels of EPO have been reported to be associated with a lower incidence of neurologic sequelae in Kenyan children infected with malaria (Casals-Pascual et al., 2008), leading to the suggestion of using this cytokine therapeutically to protect against brain damage (Casals-Pascual et al., 2009). Although a short-term open trial in Mali showed no increased mortality (Picot et al., 2009), others (John et al., 2010) have pointed out the limited opportunity to detect thrombotic side effects, the chief concern in the wider literature (Patel et al., 2011a), on using unaltered erythropoietin. Meanwhile, there appears to be a consensus (Casals-Pascual et al., 2009; John et al., 2010) to await the outcome of basic studies of the EPO variants discussed earlier (Hand and Brines, 2011; Leconte et al., 2011; Patel et al., 2011b). Some of the potentially less damaging approaches depicted in Fig. 1, such as oral minocycline or inhaled insulin, could be considered in the meantime. Nevertheless, we regard EPO variants as exciting future prospects for therapeutically addressing the overarching pathway developed in this review.

C. Administering Leptin As a Counter to Insulin Resistance

Clark et al. (2011) summarized the literature on leptin and TNF having mirror image effects on AD. As noted, administering additional leptin and lowering TNF levels are both on record as improving memory and learning, reducing anxiety, lowering Aβ and hyperphosphorylated τ, reducing β-secretase activity, increasing dendritic spine growth, activating GSK-3, and activating AMP kinase-activated, pentylentetrazole-induced seizures. As we noted (Clark et al., 2011), this pattern had previously escaped recognition. A case for the centrality of insulin resistance in AD is further strengthened by the opposite effects on insulin resistance of leptin (German et al., 2010; Koch et al., 2010) and TNF, leptin reducing and TNF increasing it.

Leptin may also have additional direct effects on neurons as an antiapoptotic, proneurogenic adipokine (Paz-
Filho et al., 2010b), and its administration to leptin-deficient humans has altered brain function and increased gray matter (London et al., 2011). Leptin is currently administered in other diseases, such as lipodystrophy syndromes, hypothalamic amenorrhea, and nonalcoholic steatohepatitis, but its CNS effects have not yet been thoroughly evaluated. Its endogenous levels have been negatively correlated with the risk of developing AD in lean (leptin sensitive) but not obese (leptin insensitive) older people (Lieb et al., 2009), implying that only lean people would be susceptible to treatment with leptin (Paz-Filho et al., 2010a).

Neither leptin nor anti-TNF agents yet appear to have been tested against the SZT model of AD, although leptin reduces insulin resistance (Lin et al., 2002) and leptin deficiency increases it (German et al., 2011), in the SZT model of T2DM. Because normal insulin sensitivity keeps GSK-3β activity low, administering leptin should also decrease its activation and τ hyperphosphorylation. This, too, has also been reported in neurons (Greco et al., 2009). The ability of leptin to increase insulin sensitivity has yet to be explored as an explanation for the novel observation that intracerebroventricular injection of leptin dramatically, albeit briefly, improves a wide range of pathologic features in a mouse model of type 1 diabetes (Fujikawa et al., 2010). The systemic improvements recollect those achieved, as discussed earlier, with intracerebroventricular injections of infliximab, a commercial anti-TNF biological agent (Arvuda et al., 2011).

**D. Administering Insulin As a Counter to Insulin Resistance**

Interest in this approach to treating AD appears to have arisen when it was realized that the temporary memory improvement in patient brain function after systemic administration of insulin was independent of the attendant serum glucose concentration (Craft et al., 1996, 1999). Evidently, more subtle pathways are at work. Others found that the effects of intranasal insulin could alter basic central nervous system function in euglycemic healthy volunteers (Kern et al., 1999) and a few years later documented the changes in CSF levels of insulin so caused, as well as the absence of systemic changes in insulin or glucose (Born et al., 2002). By 2004 (Benedict et al., 2004), they had reported improvements, in a similar group of healthy volunteers, in memory and mood after 8 weeks of treatment. Soon after, another group reported a pilot trial that exhibited memory improvement after this treatment in patients with AD (Reger et al., 2006). They also reported, then and subsequently (Reger et al., 2008), that responses were absent, under the conditions tested, in apolipoprotein E (apoE)-4-positive patients. Given that a major controller of insulin resistance is the inflammatory cytokine TNF (see section V.C), it is important, when considering possible reasons for this difference, to take into account the interactions between apoE4+ and TNF. One study of possible relevance, as yet unexplored, concerns the inflammatory status of microglia (and thus effects on insulin resistance, although this was not in their protocol) from mice expressing different numbers and types of human apoE genes (Vitek et al., 2009). This is discussed further in section XI.H.

Ott et al. (2012) discussed the pitfalls and potential of intranasal insulin administration on cognitive function in general, and Ketterer et al. (2011) focused on possible ways, through new insulin analogs, such as aspart and detemir, to optimize reduction of cerebral insulin resistance. Subsequently, Benedict et al. (2012) and Schöth et al. (2012) documented an association between impaired insulin resistance with deficits in verbal fluency and temporal lobe gray matter volume in the elderly and evaluated the therapeutic potential of reversing this resistance with intranasal insulin. The former of these publications is reminiscent of the association observed between insulin resistance and executive function (Abbatecola et al., 2004).

**E. Glucagon-Like Peptide-1 Mimetics and Dipeptidyl Peptidase-4 Inhibitors As Counters to Insulin Resistance**

Being rapidly degraded (minutes) in vivo by DPP-4 (see section V.E), native GLP-1 is impractical as a therapy. Hence, degradation-resistant GLP-1 receptor agonists, often termed GLP-1 mimetics, have been developed (Ahren, 2011a,b), and a number of these agents are in therapeutic use subcutaneously in T2DM. Exenatide is an example from a group of drugs based on exendin-4, a GLP-1-like molecule isolated from a reptile. Another approach, based on synthesizing GLP-1 analogs, has led to other subcutaneous agents, such as liraglutide (Buse et al., 2009). Both of these types of GLP-1 mimetics pass through the blood-brain barrier and have proved to be strikingly active against AD models (Perry et al., 2003; Liu et al., 2009; Porter et al., 2010; Li et al., 2011; McClean et al., 2011) as well as against a model of the cognitive defects in T2DM (Gault et al., 2010). Recent basic studies give impressively detailed reinforcement to this approach (Bomfim et al., 2012; Talbot et al., 2012). In addition, a number of agents have been developed, such as sitagliptin, which inhibits the catalytic site of DPP-4 (Ahren and Foley, 2008; Ahren, 2009) to extend the life of endogenous GLP-1. They are marketed for treating T2DM and have the practical advantage of being administered orally, although their testing in AD models remains in its infancy (D’Amico et al., 2010).

**F. Glycogen Synthase Kinase-3 Antagonists**

SB216763, presumably tested for its effects on endotoxin-treated human monocytes (Martin et al., 2005), showed a degree of promise in a model of AD generated by injecting an Aβ oligomer into aged rats but made outcomes worse in control rats (Hu et al., 2009). As this group suggested, less
potent inhibitors that do not inhibit constitutional GSK-3 may be necessary. The study by Engel et al. (2006) is consistent with this. In terms of lowering phosphorylated τ levels and decreasing spatial memory loss, others successfully tested a GSK-3 inhibitor, a thiazolidinone termed 4-benzyl-2-methyl-1,2,4-thiazolidine-3,5-dione (NP12), in a transgenic mouse model of AD (Serenò et al., 2009). However, the mice did not live longer. 2-Methyl-5-(3-[4-[(S)-methylsulfinyl]phenyl]-1-benzofuran-5-yl)-1,3,4-oxadiazole, another novel GSK-3 inhibitor, has recently been reported to produce a similar positive outcome in vitro and in a mouse model (Onishi et al., 2011). Successfully targeting GSK-3, now a goal in many disease fields, is evidently a complex undertaking. Engagingly, cardiac researchers have referred to the challenge it presents as a very sharp double-edged sword (Cheng et al., 2011). This approach, as well as those discussed in the rest of this section, is shown in Fig. 1. The major treatment concepts and their intended or predictable consequences are collected in Table 1.

H. Apolipoprotein E Mimetics and Bexarotene

As reviewed by Laskowitz et al. (2001), the protein apoE was identified by its role in the transport and metabolism of cholesterol and triglycerides. It is the major apolipoprotein generated in the brain, where it originates from glial cells. Human genetic variation accommodates three isoforms: apoE2, apoE3 (the most common), and apoE4. In brief, the more apoE4 generated, the less functional apoE protein is present (Riddell et al., 2008). Almost as soon as it was appreciated that the presence of the apoE4 allele was robustly associated with an increased risk of developing most forms of AD (Corder et al., 1993), two apparently unrelated threads with an increased risk of developing most forms of AD (Strittmatter et al., 1993, 1994). The other thread, not lipid-related, focusing on innate immunity and inflammatory mediators rather than lipids, sought to explain why the link between apoE4 and disease risk was far wider than AD, encompassing traumatic brain injury and stroke, and bacterial infections (Roselaar and Daugherty, 1998; de Bont et al., 1999), which have all been argued to be inflammatory conditions since the early 1990s. Indeed, the apoE4 connection with disease susceptibility goes as far as HIV dementia (Corder et al., 1998) and cerebral malaria (Aucan et al., 2004).

This second line of enquiry led to seminal outcomes such as suppression of glial cell secretion of TNF by apoE (Laskowitz et al., 1997) and inhibition of glial cell activation and the endogenous CNS inflammatory response (Lynch et al., 2001) and the general type 1 inflammatory response (Ali et al., 2005), which is mediated by cytokines such as TNF and IL-1β. A comprehensive review of these concepts appeared 3 years ago (Vitek et al., 2009). This approach has led to the attainment of a clinically useful anti-inflammatory milieu in many mouse models of inflammatory disease by subcutaneous injection of segments of the apoE molecule (apoE mimetics) that are small enough to enter the brain. This duplicates the anti-inflammatory action of complete apoE (Laskowitz et al., 2001). Examples include traumatic brain injury (Lynch et al., 2005; Laskowitz et al., 2007; Hoane et al., 2009; Kaufman et al., 2010), stroke (Tukhovskaya et al., 2009), and AD (Vitek et al., 2012).

Cramer et al. (2012) describe removal of Aβ plaque and correction of functional deficits in a strain of mice prone to AD-like changes after oral administration of bexarotene, an anti-tumor drug in clinical use. This agent is small enough to enter the brain, where it increases endogenous apoE levels through its activity as a retinoid X receptor agonist. In a functional sense, bexarotene therefore promises to be the equivalent of the apoE mimetics. Surprisingly, Aβ plaque removal was the only mechanism considered by these authors, despite the doubt cast on the utility of this endpoint by the AD patient trial of AN1792 (AP42; Elan Pharmaceuticals, South San Francisco, CA) several years ago (Holmes et al., 2008). It is useful to recall, when interpreting

<table>
<thead>
<tr>
<th>Treatment Concepts</th>
<th>Predictable Consequences in the Brain</th>
<th>Predictable Downstream Consequences in the Brain</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>apoE mimetics</td>
<td>TNF</td>
<td>Insulin resistance</td>
<td>Laskowitz et al., 2001</td>
</tr>
<tr>
<td>Thalidomide derivatives</td>
<td>TNF</td>
<td>Insulin resistance</td>
<td>Greig et al., 2004a</td>
</tr>
<tr>
<td>Anti-TNF biologicals</td>
<td>TNF</td>
<td>Insulin resistance</td>
<td>Tohnik et al., 2006</td>
</tr>
<tr>
<td>Minocycline</td>
<td>TNF</td>
<td>Insulin resistance</td>
<td>Seabrook et al., 2006</td>
</tr>
<tr>
<td>Leuprolide</td>
<td>TNF</td>
<td>Insulin resistance</td>
<td>Clark and Atwood, 2011</td>
</tr>
<tr>
<td>Curcumin derivatives</td>
<td>TNF</td>
<td>Insulin resistance</td>
<td>Tsai et al., 2011</td>
</tr>
<tr>
<td>Erythropoietin</td>
<td>TNF</td>
<td>Insulin resistance</td>
<td>Nairz et al., 2011a</td>
</tr>
<tr>
<td>Bexarotene</td>
<td>TNF</td>
<td>Insulin resistance</td>
<td>Cramer et al., 2012</td>
</tr>
<tr>
<td>GLP-1 mimetics</td>
<td>Insulin resistance</td>
<td>GSK3 activation</td>
<td>Perry et al., 2003</td>
</tr>
<tr>
<td>Intranasal insulin</td>
<td>Insulin resistance</td>
<td>GSK3 activation</td>
<td>Benedet et al., 2004</td>
</tr>
<tr>
<td>Leptin</td>
<td>Insulin resistance</td>
<td>GSK3 activation</td>
<td>Koch et al., 2010</td>
</tr>
<tr>
<td>DPP-4 inhibitors</td>
<td>Insulin resistance</td>
<td>GSK3 activation</td>
<td>D’Amico et al., 2010</td>
</tr>
<tr>
<td>GSK-3 antagonists</td>
<td>GSK3 activation</td>
<td>Harmful enzyme phosphorylation</td>
<td>Onishi et al., 2011</td>
</tr>
</tbody>
</table>

|                                                                 | |
|[, reduction.                                                      | |
this hexaborate data, that anti-TNF treatment produces a very similar outcome in the same mouse model (Shi et al., 2011), and an apoE mimetic has since done so in a related mouse strain (Vitek et al., 2012). Literature exists on the side effects of hexaborate, but whether these arise from high apoE or other consequences of retinoid X receptor activation has yet to be determined.

XII. Conclusions

It seems not yet to have been taken into account in AD research that TNF and related inflammatory cytokines induce insulin resistance or that SZT also induces TNF. The introduction of these concepts into this field consolidates numerous non-αβ models of AD. Accordingly, numerous proposed treatments for AD, presently undertaken with different rationales, seem to be functionally linked by events that lower TNF levels (and thus insulin resistance), lower insulin resistance directly, or deal with its consequences. These presently independent sets of arguments for therapy reinforce the logic of chronic cerebral insulin resistance and, therefore, the degree to which GSK-3 activation, and thus mitochondrial dysfunction, is central to understanding this disease. We have reasoned that these superficially unrelated approaches to treatment are all aimed at chronic inflammation and its consequences. Thus, they are, in a sense, one tool, which invites collaborative searches for therapeutic synergy.

When considering how rapidly the therapies discussed in this review might have the opportunity to demonstrate whether they can help patients, we note that anti-TNF biological agents, minocycline, and GLP-1 mimetics already have a history of clinical use for other conditions, the first two for much longer, and on a much larger scale, than the third. Intranasal insulin has been used in human trials, produced no side effects, and in a small number of patients without apparent harm, whereas EPO variants still require basic toxicity and larger scale, than the third. Intranasal insulin has been suggested numerous proposed treatments for AD, presently under-


Ali K, Middleton M, Pure E, and Rader DJ (2005) Apolipoprotein E suppresses the re-ceptor activation has yet to be determined.

References


Best worst


controls in mice with high fat dietary-induced obesity and insulin resistance. Diabetes 58:1298–1308.


Trends Neurosci 26:2798–2806.


